miR-429 as biomarker for diagnosis, treatment and prognosis of cancers and its potential action mechanisms: A systematic literature review.
This article summarizes the associations between miR-429 and malignant tumors as well as potential action mechanisms. miR-429 has a potential to be used in the future as a biomarker for the diagnosis, treatment and prognosis of certain cancers. PMID: 31884798 [PubMed - as supplied by publisher]
Skeletal muscle atrophy is a major consequence of several pathophysiological conditions, including neuromuscular diseases, disuse (limb immobilization, space flight), aging (sarcopenia) and other wasting conditions (i.e. cancer cachexia). Basically, a disequilibrium between anabolic/catabolic pathways leads to progressive loss of muscle mass and functional impairment. The aim of translational research in this field is to identify anabolic compounds able to support protein synthesis and muscle mass, restoring muscle function and metabolism.
We report our case, along with the relevant literature. The patient is a 70-year-old man. Twelve years ago, he was diagnosed with anti-acetylcholine receptor antibody (anti-Ach-R Ab)-positive systemic MG. He underwent thymectomy and was treated with oral steroids.
Dermatomyositis (DM) is a rare and systemic autoimmune disease belonging to the idiopathic inflammatory myopathies, primarily affecting skeletal muscle and skin. However, other organs might be affected, like the lung, heart or arteries, and development of cancer might also be associated with DM. For diagnostic and prognostic management, the detection of one of the associated autoantibodies (aAB, e.g. Mi-2, NXP-2, MDA5 TIF1 γ and rarely SAE) is of outmost importance, since associations between these antibodies and interstitial lung disease (ILD) or cancer (e.g.
Dermatomyositis (DM) can be associated with the anti-melanoma differentiation-associated gene 5 (MDA5, IFIH1) autoantibody. Of note, patients present with severe extramuscular (notably lung and skin) manifestations and myopathy can be mild or missing, hence termed ``amyopathic'' DM previously. Interstitial lung disease is the leading cause of death in MDA5-DM, and death occurs frequently within one year after diagnosis in roughly 30% of these DM patients. We hereby report the autoptic findings of two male patients (30 and 42 years old) who succumbed to severe ILD in MDA5-related DM.
Inflammatory myopathies consist of heterogenous group of immune-mediated muscle diseases including dermatomyositis, polymyositis and so on. Patients with inflammatory myopathies occasionally have malignancies such as breast, lung, colorectal cancer and nasopharyngeal carcinoma. There have been a few reports of patients with inflammatory myopathy and lymphoma. Herein, we report an unusual case of a 67-year-old male with inflammatory myopathy and diffuse large B cell lymphoma who initially presented with slowly progressive quadriparesis, axial weakness and abnormality in the electromyography and muscle magnetic resonance image (MRI).
The objective of this study was to prepare the liver targeting drug delivery system (TDDS) of artesunate (ART)-loaded polyethylene glycol (PEG)-Poly (D, L-lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) modified by glycyrrhetinic acid (GA), and evaluate its in vitro cytotoxicity.Significance: The GA-PEG-PLGA-ART NPs enhanced the in vitro cytotoxicity on HCC cell lines. The development of GA-PEG-PLGA NPs will greatly push the clinical applications of ART as a novel anticancer drug.Methods: The NPs were prepared using solvent evaporation method, and the formulation was optimized through an orthogonal design. In addition,...
PMID: 32976788 [PubMed - as supplied by publisher]
BOWEL cancer symptoms include weight loss, stomach pain, and feeling very tired for no obvious reason. But you could also be at risk of the disease if you notice a change to your toilet habit. These are the two colours of poo that could be caused by something serious. Should you check the colour of your stools?
In conclusion, it remains unclear if brain-specific regional and temporal changes occur in the expression of the different APP variants during AD progression. Since APP is also found in blood cells, assessing the changes in APP mRNA expression in peripheral blood cells from AD patients has been considering an alternative. However, again the quantification of APP mRNA in peripheral blood cells has generated controversial results. Brain APP protein has been analyzed in only a few studies, probably as it is difficult to interpret the complex pattern of APP variants and fragments. We previously characterized the soluabl...
Abstract Long non-coding RNAs (lncRNAs) cancer susceptibility candidate 2 (CASC2) has been characterized as a tumor suppressor in glioma. Although CASC2 may predict the prognosis of glioma patients, the role and mechanism of CASC2 in human glioblastoma remain to be fully illuminated. Expression of CASC2 and miR- 18a was detected using RT-qPCR. Cell growth was evaluated by MTT assay, colony formation assay, and flow cytometry; metastasis and epithelial-mesenchymal transition (EMT) were determined with transwell assay and Western blot, respectively. The target binding between CASC2 and miR-18a was predicted on Starb...
More News: Bladder Cancer | Bone Cancers | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Colorectal Cancer | Endometrial Cancer | Epithelial Cancer | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Hepatocellular Carcinoma | Kidney Cancer | Liver Cancer | Lung Cancer | Nasopharyngeal Cancer | Oral Cancer | Osteosarcoma | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Prostate Cancer | Renal Cell Carcinoma | Sarcomas | Skin Cancer | Soft Tissue Sarcoma | Squamous Cell Carcinoma